Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Hypergammaglobulinemia and Impaired Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea.

Atwell JE, Thumar B, Formica MA, Robinson LJ, Walsh EE, King CL, Karron RA.

Pediatr Infect Dis J. 2019 Sep;38(9):e199-e202. doi: 10.1097/INF.0000000000002364.

PMID:
31408055
2.

Live-Attenuated Respiratory Syncytial Virus Vaccine With Deletion of RNA Synthesis Regulatory Protein M2-2 and Cold Passage Mutations Is Overattenuated.

Cunningham CK, Karron R, Muresan P, McFarland EJ, Perlowski C, Libous J, Thumar B, Gnanashanmugam D, Moye J Jr, Schappell E, Barr E, Rexroad V, Aziz M, Deville J, Rutstein R, Yang L, Luongo C, Collins P, Buchholz U; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2012 Study Team.

Open Forum Infect Dis. 2019 May 6;6(6):ofz212. doi: 10.1093/ofid/ofz212. eCollection 2019 Jun.

3.

Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children.

Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 Study Team.

J Infect Dis. 2018 Apr 11;217(9):1338-1346. doi: 10.1093/infdis/jiy066.

4.

Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate With Deletion of RNA Synthesis Regulatory Protein M2-2 is Highly Immunogenic in Children.

McFarland EJ, Karron RA, Muresan P, Cunningham CK, Valentine ME, Perlowski C, Thumar B, Gnanashanmugam D, Siberry GK, Schappell E, Barr E, Rexroad V, Yogev R, Spector SA, Aziz M, Patel N, Cielo M, Luongo C, Collins PL, Buchholz UJ; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2000 Study Team.

J Infect Dis. 2018 Apr 11;217(9):1347-1355. doi: 10.1093/infdis/jiy040.

5.

Evaluation of a Live-Attenuated Human Parainfluenza Type 1 Vaccine in Adults and Children.

Karron RA, San Mateo J, Thumar B, Schaap-Nutt A, Buchholz UJ, Schmidt AC, Bartlett EJ, Murphy BR, Collins PL.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):e143-6. doi: 10.1093/jpids/piu104. Epub 2014 Nov 12.

6.

A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.

Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, Buchholz UJ.

Sci Transl Med. 2015 Nov 4;7(312):312ra175. doi: 10.1126/scitranslmed.aac8463.

7.

Impact of Placental Malaria and Hypergammaglobulinemia on Transplacental Transfer of Respiratory Syncytial Virus Antibody in Papua New Guinea.

Atwell JE, Thumar B, Robinson LJ, Tobby R, Yambo P, Ome-Kaius M, Siba PM, Unger HW, Rogerson SJ, King CL, Karron RA.

J Infect Dis. 2016 Feb 1;213(3):423-31. doi: 10.1093/infdis/jiv401. Epub 2015 Aug 3.

8.

Evaluation of fast-track diagnostics and TaqMan array card real-time PCR assays for the detection of respiratory pathogens.

Driscoll AJ, Karron RA, Bhat N, Thumar B, Kodani M, Fields BS, Whitney CG, Levine OS, O'Brien KL, Murdoch DR.

J Microbiol Methods. 2014 Dec;107:222-6.

PMID:
25448378
9.

Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes.

Seo S, Xie H, Karron RA, Thumar B, Englund JA, Leisenring WM, Stevens-Ayers T, Boeckh M, Campbell AP.

Bone Marrow Transplant. 2014 Sep;49(9):1205-11. doi: 10.1038/bmt.2014.124. Epub 2014 Jun 30.

10.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group.

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

11.

Experimental infection of adults with recombinant wild-type human metapneumovirus.

Talaat KR, Karron RA, Thumar B, McMahon BA, Schmidt AC, Collins PL, Buchholz UJ.

J Infect Dis. 2013 Nov 15;208(10):1669-78. doi: 10.1093/infdis/jit356. Epub 2013 Aug 1.

12.

Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines.

Karron RA, Thumar B, Schappell E, Buchholz UJ, Collins PL.

J Infect Dis. 2013 Jun 1;207(11):1773-9. doi: 10.1093/infdis/jit089. Epub 2013 Mar 12.

13.

An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.

Talaat KR, Karron RA, Liang PH, McMahon BA, Luke CJ, Thumar B, Chen GL, Min JY, Lamirande EW, Jin H, Coelingh KL, Kemble GW, Subbarao K.

Influenza Other Respir Viruses. 2013 Jan;7(1):66-73. doi: 10.1111/j.1750-2659.2012.00350.x. Epub 2012 Mar 14.

14.

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.

15.

A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial.

Durbin AP, Whitehead SS, Shaffer D, Elwood D, Wanionek K, Thumar B, Blaney JE, Murphy BR, Schmidt AC.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1267. doi: 10.1371/journal.pntd.0001267. Epub 2011 Aug 2.

16.

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC.

Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f.

17.

An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults.

Talaat KR, Karron RA, Luke CJ, Thumar B, McMahon BA, Chen GL, Lamirande EW, Jin H, Coelingh KL, Kemble G, Subbarao K.

Vaccine. 2011 Apr 12;29(17):3144-8. doi: 10.1016/j.vaccine.2011.02.043. Epub 2011 Mar 4.

18.

Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic.

Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS.

J Infect Dis. 2011 Feb 1;203(3):327-34. doi: 10.1093/infdis/jiq059. Epub 2010 Dec 14.

19.

Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.

Wright PF, Durbin AP, Whitehead SS, Ikizler MR, Henderson S, Blaney JE, Thumar B, Ankrah S, Rock MT, McKinney BA, Murphy BR, Schmidt AC.

Am J Trop Med Hyg. 2009 Nov;81(5):834-41. doi: 10.4269/ajtmh.2009.09-0131.

20.

Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.

Karron RA, Talaat K, Luke C, Callahan K, Thumar B, Dilorenzo S, McAuliffe J, Schappell E, Suguitan A, Mills K, Chen G, Lamirande E, Coelingh K, Jin H, Murphy BR, Kemble G, Subbarao K.

Vaccine. 2009 Aug 6;27(36):4953-60. doi: 10.1016/j.vaccine.2009.05.099. Epub 2009 Jun 21.

21.

A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K.

J Infect Dis. 2009 Mar 1;199(5):711-6. doi: 10.1086/596558.

22.

Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity.

McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2008 Nov;79(5):678-84.

23.

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron RA.

J Infect Dis. 2008 Oct 1;198(7):1007-15. doi: 10.1086/591460.

PMID:
18702606
24.

The role of neutralizing antibodies in protection of American Indian infants against respiratory syncytial virus disease.

Eick A, Karron R, Shaw J, Thumar B, Reid R, Santosham M, O'Brien KL.

Pediatr Infect Dis J. 2008 Mar;27(3):207-12. doi: 10.1097/INF.0b013e31815ac585.

PMID:
18277934
25.

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, Wanionek K, Murphy BR, Whitehead SS.

Hum Vaccin. 2006 Nov-Dec;2(6):255-60. Epub 2006 Nov 5.

PMID:
17106267
26.

C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Melendi GA, Hoffman SJ, Karron RA, Irusta PM, Laham FR, Humbles A, Schofield B, Pan CH, Rabold R, Thumar B, Thumar A, Gerard NP, Mitzner W, Barnum SR, Gerard C, Kleeberger SR, Polack FP.

J Virol. 2007 Jan;81(2):991-9. Epub 2006 Nov 1.

27.

The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.

Durbin AP, McArthur J, Marron JA, Blaney JE Jr, Thumar B, Wanionek K, Murphy BR, Whitehead SS.

Hum Vaccin. 2006 Jul-Aug;2(4):167-73. Epub 2006 Jul 24.

PMID:
17012875
28.

The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin.

Polack FP, Irusta PM, Hoffman SJ, Schiatti MP, Melendi GA, Delgado MF, Laham FR, Thumar B, Hendry RM, Melero JA, Karron RA, Collins PL, Kleeberger SR.

Proc Natl Acad Sci U S A. 2005 Jun 21;102(25):8996-9001. Epub 2005 Jun 14.

29.

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.

J Infect Dis. 2005 Apr 1;191(7):1093-104. Epub 2005 Mar 1.

PMID:
15747245
30.

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.

Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE Jr, Thumar B, Murphy BR, Karron RA.

J Infect Dis. 2005 Mar 1;191(5):710-8. Epub 2005 Jan 27.

PMID:
15688284
31.

Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy.

Laham FR, Israele V, Casellas JM, Garcia AM, Lac Prugent CM, Hoffman SJ, Hauer D, Thumar B, Name MI, Pascual A, Taratutto N, Ishida MT, Balduzzi M, Maccarone M, Jackli S, Passarino R, Gaivironsky RA, Karron RA, Polack NR, Polack FP.

J Infect Dis. 2004 Jun 1;189(11):2047-56. Epub 2004 May 6.

PMID:
15143472
32.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
33.

Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.

Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, Perreault JR, Thumar B, Men R, Lai CJ, Elkins WR, Chanock RM, Murphy BR, Whitehead SS.

Am J Trop Med Hyg. 2001 Nov;65(5):405-13.

PMID:
11716091
34.

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy.

Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR.

J Infect Dis. 2000 Nov;182(5):1331-42. Epub 2000 Sep 22.

PMID:
11010838
36.

Systemic and local antibody responses in elderly subjects given live or inactivated influenza A virus vaccines.

Powers DC, Sears SD, Murphy BR, Thumar B, Clements ML.

J Clin Microbiol. 1989 Dec;27(12):2666-71.

37.

Susceptibility testing of filamentous fungi to amphotericin B by a rapid radiometric method.

Merz WG, Fay D, Thumar B, Dixon D.

J Clin Microbiol. 1984 Jan;19(1):54-6.

Supplemental Content

Loading ...
Support Center